Uptake of amino acids by actidione-treated yeast cells. II. Effect of incubation conditions and metabolic inhibitors.
D000081:Acetamides / Q000494:pharmacology; D000085:Acetates / Q000494:pharmacology; D000577:Amides / Q000494:pharmacology; D000596:Amino Acids / Q000378:metabolism*; D000693:Anaerobiosis; D001224:Aspartic Acid / Q000037:antagonists & inhibitors / Q000378:metabolism; D001386:Azides / Q000494:pharmacology; D002208:Caproates / Q000494:pharmacology; D003513:Cycloheximide / Q000494:pharmacology*; D004140:Dinitrophenols / Q000494:pharmacology; D005459:Fluorides / Q000494:pharmacology; D005998:Glycine / Q000037:antagonists & inhibitors / Q000378:metabolism; D006863:Hydrogen-Ion Concentration; D007461:Iodoacetates / Q000494:pharmacology; D008239:Lysine / Q000037:antagonists & inhibitors / Q000378:metabolism; D012440:Saccharomyces / Q000187:drug effects* / Q000378:metabolism; D012441:Saccharomyces cerevisiae / Q000187:drug effects; D014501:Uranium / Q000494:pharmacology
D000081:Acetamides; D000085:Acetates; D000577:Amides; D000596:Amino Acids; D001386:Azides; D002208:Caproates; D004140:Dinitrophenols; D007461:Iodoacetates; D001224:Aspartic Acid; D014501:Uranium; D003513:Cycloheximide; D008239:Lysine; D005459:Fluorides; D005998:Glycine